The Optical Biopsy Blog - Mauna Kea Technologies' Official Corporate Blog

New CE Mark for Minimally-Invasive Surgery Applications for Cellvizio

Posted by Sacha Loiseau

Find me on:

August 27, 2015 at 6:06 AM

Ceres probe

This summer we entered exciting new territory at Mauna Kea Technologies, integrating Cellvizio imaging technology with OR suites in the minimally invasive surgery market. And now we have a new CE mark that will allow us to support more surgeons with immediate actionable information that can be used to optimize interventions.

 X-ray, ultrasound, MRI and CT scans are limited in their ability to provide up close views in real-time to help surgeons during a procedure. New macroscopic visualization techniques enable surgeons to get broad views with relevant information, but limited by the resolution of these cameras. At Mauna Kea Technologies we have taken the microscope to the OR, and our confocal laser endomicroscopy platform delivers cCellvizio-EVAellular images of target tissue in real-time during interventions. For patients, it means a surgeon may nothave to remove tissue for histological studies. For surgeons, it means a higher level of precision and accuracy and greater speed to appropriate intervention.We're very pleased by the string of regulatory approvals we have secured over the past few months. These approvals

give us more options for market developments with potential large scale partners.

In May, our Celioflex microscopy probe received a CE mark covering a wide range of minimally invasive surgeries in oncology. In June, the AQ-Flex 19 IR Cellvizio probe received CE mark approval for interventional radiology indications. And in the latest news, our Cellvizio 800 intra-operative platform has received a CE mark to provide near-infrared endomicroscopic imaging during minimally invasive surgical operations.

We are particularly excited about the potential for Cellvizio 800 to take fluorescence-guided surgery to the next level. A new design allows us to operate in the same setting and at the same wavelength as widely used macroscopic imaging platforms for surgery. Cellvizio 800 complements popular systems like Pinpoint® and Firefly® that rely on robotic manipulation.

Developing ways to integrate with existing platforms is a path to market that we believe to be very interesting going forward and could be the most efficient approach to bringing our technology to surgeons. We’re off to a great start this summer and look forward to more progress in the coming months. In September we are sponsoring a one-day Optical Surgical Navigation seminar, “Device, Dyes, Applications & the Regulatory Process,” hosted by the American Society of Image Guided Surgery (ASIGS) and the WMIC-2015bannersmallWorld Molecular Imaging Society (WMIS) during the 8th Annual World Molecular Imaging Congress at the Hawaii Convention Center. The agenda includes a panel discussion on devices for surgical imaging and a review of recent research with new probes. It’s a great opportunity to learn more about optical molecular imaging and translation to clinical use. If you plan on attending or would like more information, leave us a comment on this post or send me a note on Twitter @sachaloiseau.  

Cellvizio, Mauna Kea Technologies, Optical Biopsy

Topics: Mauna Kea Technologies, Company news, Endomicroscopy, Surgery


About this blog

The latest news and information about Mauna Kea Technologies and Cellvizio Optical Biopsy, the Fastest Way to See Cancer. 

Subscribe to Email Updates